# Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease

> **NCT02434718** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 21 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Aducanumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02434718
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-24
- **Primary completion:** 2016-12-09
- **Final completion:** 2016-12-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02434718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02434718, "Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02434718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*